

CORRECTION
[View Article Online](#)
[View Journal](#) | [View Issue](#)

 Cite this: *RSC Adv.*, 2026, **16**, 8693

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

 Marwa N. Rahimi,^{ab} Jo-Anne Pinson,^{ab} Joseph Hilton-Proctor,^{ab} Jessica Van Zuylekom,^{bc} Benjamin Blyth,^{bc} Peter D. Roselt^{ab} and Mohammad B. Haskali^{*ab}

DOI: 10.1039/d6ra90008a

rsc.li/rsc-advances

 Correction for 'Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting' by Marwa N. Rahimi *et al.*, *RSC Adv.*, 2026, **16**, 2123–2132, <https://doi.org/10.1039/D5RA08789A>.

The authors regret that chemical structures in Fig. 1 were incorrectly shown in the original article. The amended Fig. 1 is shown below with *N*-methylation of the C-terminal naphthylalanine residue for structures GA4 and GA13.

^aDepartment of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia. E-mail: mo.haskali@petermac.org

^bSir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia

^cModels of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Victoria 3000, Australia






Fig. 1 Chemical structures of CCK₂R targeting peptides CP04, GA4, and GA13.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

